Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Gumus, Mahmut; Chen, Chieh-I; Ivanescu, Cristina; Kilickap, Saadettin; Bondarenko, Igor; Ozguroglu, Mustafa; Gogishvili, Miranda; Turk, Haci M.; Cicin, Irfan; Harnett, James; Mastey, Vera; Naumann, Ulrike; Reaney, Matthew; Konidaris, Gerasimos; Sasane, Medha; Brady, Keri; Li, Siyu; Gullo, Giuseppe; Rietschel, Petra; Sezer, Ahmet

Publication:
Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

dc.contributor.author	Gumus, Mahmut
dc.contributor.author	Chen, Chieh-I
dc.contributor.author	Ivanescu, Cristina
dc.contributor.author	Kilickap, Saadettin
dc.contributor.author	Bondarenko, Igor
dc.contributor.author	Ozguroglu, Mustafa
dc.contributor.author	Gogishvili, Miranda
dc.contributor.author	Turk, Haci M.
dc.contributor.author	Cicin, Irfan
dc.contributor.author	Harnett, James
dc.contributor.author	Mastey, Vera
dc.contributor.author	Naumann, Ulrike
dc.contributor.author	Reaney, Matthew
dc.contributor.author	Konidaris, Gerasimos
dc.contributor.author	Sasane, Medha
dc.contributor.author	Brady, Keri
dc.contributor.author	Li, Siyu
dc.contributor.author	Gullo, Giuseppe
dc.contributor.author	Rietschel, Petra
dc.contributor.author	Sezer, Ahmet
dc.date.accessioned	2021-11-30T20:59:21Z
dc.date.available	2021-11-30T20:59:21Z
dc.date.issued	2021-05-01T00:00:00Z
dc.identifier.citation	Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Harnett J., et al., -Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.doi	10.1200/jco.2021.39.15_suppl.9078
dc.identifier.uri	http://hdl.handle.net/20.500.12645/29674
dc.identifier.wos	WOS:000708120605058
dc.title	Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
dc.type	Article
dspace.entity.type	Publication
local.avesis.id	8e492aa8-7b9e-4cc6-b83b-87a0add76a41
local.indexed.at	WOS
local.publication.isinternational	1

Collections

Yayınlar - Eserler

Publication: Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Files

Collections

Publication:
Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.